Scarica l'app Stockscreener
19.41
3.52%
0.66
Pre-mercato:
20.46
1.05
+5.41%
Precedente Chiudi:
$18.75
Aprire:
$18.83
Volume 24 ore:
1.03M
Relative Volume:
0.58
Capitalizzazione di mercato:
$1.97B
Reddito:
$54.55M
Utile/perdita netta:
$-193.57M
Rapporto P/E:
-6.7163
EPS:
-2.89
Flusso di cassa netto:
$-181.86M
1 W Prestazione:
+6.41%
1M Prestazione:
+0.57%
6M Prestazione:
+68.49%
1 anno Prestazione:
-2.02%
Intervallo 1D:
$18.62
$19.65
Intervallo di 1 settimana:
$18.15
$20.18
Portata 52W:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Confronta NRIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
19.41 | 1.90B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-03-17 | Iniziato | Leerink Partners | Market Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Aug PreEarnings: What is the next catalyst for Nurix Therapeutics Inc2025 Earnings Surprises & Technical Analysis for Trade Confirmation - baoquankhu1.vn
EPS Watch: Will Nurix Therapeutics Inc outperform the market in YEARJuly 2025 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
Insider Buy: Can Nurix Therapeutics Inc sustain its profitability2025 Bull vs Bear & Weekly Momentum Stock Picks - baoquankhu1.vn
Insider Buy: Will Nurix Therapeutics Inc outperform the market in YEARMarket Trend Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Assessing Nurix Therapeutics (NRIX) Valuation After Recent Share Price Volatility - Yahoo Finance
(NRIX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Cuts Target Price to $28 - 富途牛牛
Nurix Therapeutics chief legal officer Ring sells $69,273 in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics chief legal officer Ring sells $69,273 in stock - Investing.com
RBC Trims Price Target on Nurix Therapeutics to $28 From $29, Keeps Outperform, Speculative Risk - marketscreener.com
Nurix Therapeutics (NRIX) to Release Earnings on Tuesday - MarketBeat
Market Rankings: What is the next catalyst for Nurix Therapeutics IncJuly 2025 Price Swings & Verified Swing Trading Watchlists - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know - sharewise.com
Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX) - Seeking Alpha
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - The AI Journal
Aug Fed Impact: Is Contango Ore Inc attractive for institutional investorsJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - baoquankhu1.vn
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
BTIG reiterates Buy rating on Nurix stock with $30 price target - Investing.com UK
Sectors Review: Is Nurix Therapeutics Inc a stock for growth or value investorsJuly 2025 Movers & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Volume Summary: Why Nurix Therapeutics Inc. stock could outperform in 2025 - Bộ Nội Vụ
Nurix outlines 2026 strategy for BTK degrader bexobrutideg in pivotal trials - Investing.com Nigeria
Do Analyst Upgrades Clarify Nurix Therapeutics’ (NRIX) True Potential Or Complicate Its Valuation Story? - Sahm
NRIX: Bexabrutadeg shows best-in-class potential in CLL, driving pivotal trials and pipeline expansion - TradingView — Track All Markets
Nurix Therapeutics, Inc. Outlines 2026 Goals and Objectives - TradingView — Track All Markets
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - Investing News Network
Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside (NASDAQ:NRIX) - Seeking Alpha
Nurix outlines 2026 strategy for BTK degrader bexobrutideg in pivotal trials By Investing.com - Investing.com South Africa
Inside Nurix's push to test a new cancer and autoimmune drug in 2026 - Stock Titan
Published on: 2026-01-10 21:09:42 - ulpravda.ru
Why retail investors pile into Nurix Therapeutics Inc. stockEarnings Growth Report & Fast Entry and Exit Trade Plans - ulpravda.ru
Aug Patterns: Why Nurix Therapeutics Inc. stock appeals to analystsPortfolio Gains Summary & Daily Stock Momentum Reports - Улправда
How Nurix Therapeutics Inc. stock compares to market leadersPortfolio Profit Report & Low Risk Entry Point Guides - ulpravda.ru
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Exploring a 59% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
What 18 Analyst Ratings Have To Say About Nurix Therapeutics - Sahm
Morgan Stanley Upgrades Nurix Therapeutics (NRIX) - Nasdaq
Dow Theory LettersNurix Therapeutics, Inc.Common stock (Nasdaq:NRIX) Detailed Stock Data - FinancialContent
Will Nurix Therapeutics Inc. stock beat EPS estimates2025 Major Catalysts & Precise Swing Trade Entry Alerts - Улправда
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpStill a Buy? - MarketBeat
NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P - GuruFocus
Should I hold or sell Nurix Therapeutics Inc. stock in 20252026 world cup usa national team round of 32 goalkeepers high defensive line winner prediction statistical analysis - ulpravda.ru
User | ricentral.comNurix Therapeutics, Inc.Common stock (Nasdaq:NRIX) Stock Quote - FinancialContent
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Nurix Therapeutics Inc Stock Analysis and ForecastMarket Sentiment Extremes & High-Risk, High-Reward? We Find the Winners - earlytimes.in
NRIX Stock Price, Forecast & Analysis | NURIX THERAPEUTICS INC (NASDAQ:NRIX) - Chartmill
Trading Systems Reacting to (NRIX) Volatility - Stock Traders Daily
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is It Too Late to Sell Shiva Texyarn LimitedTechnical Breakout Signals & Discover Top Gainers in Every Sector - earlytimes.in
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):